Abstract
Pheochromocytomas and paragangliomas are highly heterogeneous neuroendocrine tumors that must be considered not only in patients with hypertension and other manifestations of catecholamine excess but also in patients with incidentalomas or mutations in one of the ten tumor susceptibility genes identified to date. To first think of the tumor remains the critical step for screening in patients with signs and symptoms. In these patients, biochemical testing is straightforward and should include measurements of plasma or urinary metanephrines, comprising separately measured normetanephrine and metanephrine. Tumors due to an underlying germline mutation are often found in the absence of hypertension or other signs or symptoms of the tumor. Screening for disease in these patients can benefit from an individualized approach according to the particular mutation. Additional measurements of methoxytyramine, the metabolite of dopamine, can be useful in patients with mutations of succinate dehydrogenase genes or patients who are at risk for malignancy.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Anderson Jr GH, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12(5):609–15.
Ariton M, Juan CS, AvRuskin TW. Pheochromocytoma: clinical observations from a Brooklyn tertiary hospital. Endocr Pract. 2000;6(3):249–52.
Omura M, Saito J, Yamaguchi K, et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;27(3):193–202.
Martell N, Rodriguez-Cerrillo M, Grobbee DE, et al. High prevalence of secondary hypertension and insulin resistance in patients with refractory hypertension. Blood Pres. 2003;12(3):149–54.
Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc. 1981;56(6):354–60.
McNeil AR, Blok BH, Koelmeyer TD, et al. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust New Zeal J Med. 2000;30(6):648–52.
Lo CY, Lam KY, Wat MS, Lam KS. Adrenal pheochromocytoma remains a frequently overlooked diagnosis. Am J Surg. 2000;179(3):212–5.
Walther MM, Reiter R, Keiser HR, et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol. 1999;162(3 Pt 1):659–64.
Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85(2):637–44.
Singh RJ. Advances in metanephrine testing for the diagnosis of pheochromocytoma. Clin Lab Med. 2004;24(1):85–103.
Pacak K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metabol. 2007;3(2):92–102.
Whiting MJ, Doogue MP. Advances in biochemical screening for phaeochromocytoma using biogenic amines. Clin Biochem Rev. 2009;30(1):3–17.
Eisenhofer G, Keiser H, Friberg P, et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab. 1998;83(6):2175–85.
Eisenhofer G, Rundquist B, Aneman A, et al. Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. J Clin Endocrinol Metab. 1995;80(10):3009–17.
Eisenhofer G, Huynh TT, Hiroi M, Pacak K. Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Rev Endocr Metab Disord. 2001;2(3):297–311.
Raber W, Raffesberg W, Bischof M, et al. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch Intern Med. 2000;160(19):2957–63.
Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287(11):1427–34.
Sawka AM, Jaeschke R, Singh RJ, Young Jr WF. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003;88:553–8.
Unger N, Pitt C, Schmidt IL, et al. Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol. 2006;154(3):409–17.
Vaclavik J, Stejskal D, Lacnak B, et al. Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients. J Hypertens. 2007;25(7):1427–31.
• Hickman PE, Leong M, Chang J, et al. Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytoma. Pathology. 2009;41(2):173–7. This study confirms the diagnostic superiority of plasma free metanephrines over other biochemical tests for the diagnosis of pheochromocytoma.
Perry CG, Sawka AM, Singh R, et al. The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma. Clin Endocrinol (Oxf). 2007;66(5):703–8.
Eisenhofer G. Free or total metanephrines for diagnosis of pheochromocytoma: what is the difference? Clin Chem. 2001;47(6):988–9.
Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev. 2004;56(3):331–49.
Lenders JW, Keiser HR, Goldstein DS, et al. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med. 1995;123(2):101–9.
• de Jong WH, Eisenhofer G, Post WJ, et al. Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors. J Clin Endocrinol Metab. 2009;94(8):2841–9. This study established that plasma and urinary methoxytyramine, as well as urinary normetanephrine, were increased by common food sources containing catecholamines. These findings indicate the importance of an overnight fast before sampling of blood for measurements of plasma methoxytyramine and more extended dietary restrictions for urinary measurements.
• Yu R, Wei M. False positive test results for pheochromocytoma from 2000 to 2008. Exp Clin Endocrinol Diabetes. 2010;118(9):577–85. False-positive test results of biochemical testing were examined in this retrospective analysis, which established a particularly high rate for testing of urinary metanephrines, mainly because of physiological influences, effects of medications, and laboratory error.
• Peaston RT, Graham KS, Chambers E, et al. Performance of plasma free metanephrines measured by liquid chromatography-tandem mass spectrometry in the diagnosis of pheochromocytoma. Clin Chim Acta. 2010;411(7–8):546–52. This is an examination of the utility of LC-MS/MS measurements of plasma metanephrines for the diagnosis of pheochromocytoma in comparison to enzyme immunoassay measurements. The study established a useful mass spectrometric method but also showed negative bias of immunoassay measurements with subsequent propensity for false-negative test results.
Pillai D, Ross HA, Kratzsch J, et al. Proficiency test of plasma free and total metanephrines: report from a study group. Clin Chem Lab Med. 2009;47:786–90.
• Pillai D, Callen S. Pilot quality assurance programme for plasma metanephrines. Ann Clin Biochem. 2010;47(Pt 2):137–42. This is a summary of the results of an interlaboratory quality assurance program examining the accuracy and precision of different assay methods for measuring plasma free metanephrines. The analysis indicates limited diagnostic precision of immunoassay measurements. The accuracy data suggest negative bias.
Lenders JW, Willemsen JJ, Eisenhofer G, et al. Is supine rest necessary before blood sampling for plasma metanephrines? Clin Chem. 2007;53(2):352–4.
Young Jr WF. Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism. Rev Endocr Metab Disord. 2007;8(4):309–20.
Grossman A, Pacak K, Sawka A, et al. Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus? Ann N Y Acad Sci. 2006;1073:332–47.
Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab. 2003;88(6):2656–66.
Eisenhofer G, Friberg P, Pacak K, et al. Plasma metadrenalines: do they provide useful information about sympatho-adrenal function and catecholamine metabolism? Clin Sci (Lond). 1995;88(5):533–42.
Bravo EL, Tarazi RC, Fouad FM, et al. Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. N Engl J Med. 1981;305(11):623–6.
Mannelli M, Ercolino T, Giache V, et al. Genetic screening for pheochromocytoma: should SDHC gene analysis be included? J Med Genet. 2007;44(9):586–7.
• Bayley JP, Kunst HP, Cascon A, et al. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol. 2010;11(4):366–72. This report establishes mutations of the SDHAF2 gene as a novel cause of familial paraganglioma.
•• Qin Y, Yao L, King EE, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet. 2010;42(3):229–33. This report establishes mutations of the TMEM127 gene as a novel cause of hereditary pheochromocytoma.
Burnichon N, Briere JJ, Libe R, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010;19:3011–20.
•• Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet. 2011;43(7):663–7. This report identifies the tenth pheochromocytoma susceptibility gene.
Bryant J, Farmer J, Kessler LJ, et al. Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Canc Inst. 2003;95(16):1196–204.
Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005;23(34):8812–8.
Mannelli M, Castellano M, Schiavi F, et al. Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab. 2009;94(5):1541–7.
Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet. 1997;70(2):138–43.
Eisenhofer G, Timmers H, Lenders JW, et al. Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. J Clin Endocrinol Metab. 2011;96:375–84.
Gagel RF. Multiple endocrine neoplasia. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, editors. Williams textbook of endocrinology. 9th ed. Philadelphia: WB Saunders Company; 1998. p. 1627–49.
Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346(19):1459–66.
Castellano M, Mori L, Giacche M, et al. Genetic mutation screening in an Italian cohort of nonsyndromic pheochromocytoma/paraganglioma patients. Ann N Y Acad Sci. 2006;1073:156–65.
Baysal BE, Willett-Brozick JE, Lawrence EC, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet. 2002;39(3):178–83.
• Eisenhofer G, Pacak K, Huynh TT, et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer. 2011;18(1):97–111. This article establishes mutation-dependent phenotypic differences in catecholamine biosynthetic and secretory pathways in different hereditary forms of pheochromocytoma. These differences parallel differences indicated by gene expression profiling studies.
Eisenhofer G, Bornstein SR, Brouwers FM, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Canc. 2004;11(3):423–36.
•• Eisenhofer G, Lenders JW, Siegert G, et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2011 Oct 28 (Epub ahead of print). In this report, plasma concentrations of methoxytyramine are reported as a novel biomarker of malignant pheochromocytoma. The study also establishes the relative contributions of tumor size and extra-adrenal tumor location as risk factors for metastatic disease and the contributions of both to the high risk of malignancy associated with SDHB mutations.
Remine W, Chong G, van Heerden J, et al. Current management of pheochromocytoma. Ann Surg. 1974;179:740–8.
John H, Ziegler WH, Hauri D, Jaeger P. Pheochromocytomas: can malignant potential be predicted? Urology. 1999;53(4):679–83.
Shen WT, Sturgeon C, Clark OH, et al. Should pheochromocytoma size influence surgical approach? a comparison of 90 malignant and 60 benign pheochromocytomas. Surgery. 2004;136(6):1127–9.
Ayala-Ramirez M, Feng L, Johnson MM, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011;96(3):717–25.
Feng F, Zhu Y, Wang X, et al. Predictive factors for malignant pheochromocytoma: analysis of 136 patients. J Urol. 2011;185(5):1583–90.
Park J, Song C, Park M, et al. Predictive characteristics of malignant pheochromocytoma. Korean J Urol. 2011;52(4):241–6.
Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 2003;63(17):5615–21.
Brouwers FM, Eisenhofer G, Tao JJ, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006;91(11):4505–9.
Tippett PA, McEwan AJ, Ackery DM. A re-evaluation of dopamine excretion in phaeochromocytoma. Clin Endocrinol (Oxf). 1986;25(4):401–10.
Januszewicz W, Wocial B, Januszewicz A, et al. Dopamine and dopa urinary excretion in patients with pheochromocytoma–diagnostic implications. Blood Pres. 2001;10(4):212–6.
van der Harst E, de Herder WW, de Krijger RR, et al. The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur J Endocrinol. 2002;147(1):85–94.
Disclosure
No potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Eisenhofer, G. Screening for Pheochromocytomas and Paragangliomas. Curr Hypertens Rep 14, 130–137 (2012). https://doi.org/10.1007/s11906-012-0246-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11906-012-0246-y
Keywords
- Pheochromocytoma
- Paraganglioma
- Screening
- Incidentaloma
- Adrenal
- Extra-adrenal
- Metastases
- Malignant
- Chromaffin cell tumor
- Diagnosis
- Normetanephrine
- Metanephrine
- Methoxytyramine
- Norepinephrine
- Epinephrine
- Dopamine
- Catecholamines
- von Hippel-Lindau
- Multiple endocrine neoplasia type 2
- Neurofibromatosis
- Succinate dehydrogenase